Hu Sheng-Shou
The Writing Committee of the Report on Cardiovascular Health and Diseases in China.
J Geriatr Cardiol. 2024 Jul 28;21(7):703-712. doi: 10.26599/1671-5411.2024.07.012.
The (2022) intricate landscape of cardiovascular health in China. In connection with the previous section, this seventh section of the report offers a comprehensive analysis of disorders of heart rhythm in China. In 2021, China has achieved significant development and gratifying results in many aspects of the field of arrhythmia. Left bundle branch pacing (LBBP), as an emerging pacing technique originating from China, has received widespread attention. New research results have emerged on its indications, surgical procedures, clinical evaluation, and comparison with other pacing techniques. Its feasibility, effectiveness, and safety have been basically verified, but its long-term prognosis still needs further confirmation from larger samples and longer follow-up time research results. Leadless pacemakers have begun to be used in a wider range of clinical applications, and related large sample cohort studies have been reported. In addition, there are also noteworthy new achievements in the fields of pacemaker remote programming, anticoagulation and radiofrequency catheter ablation (RFCA) therapy for atrial fibrillation, and implantable cardioverter defibrillator prevention of sudden cardiac death. In terms of clinical practice, due to COVID-19 pandemic, the number of RFCA procedures and other device implantations in China has fluctuated, but it has gradually recovered since 2020.
《2022年中国心血管健康的复杂状况》。与上一节相关,本报告的第七节对中国的心律紊乱进行了全面分析。2021年,中国在心律失常领域的许多方面都取得了显著进展和令人满意的成果。左束支起搏(LBBP)作为一项源自中国的新兴起搏技术,受到了广泛关注。在其适应症、手术操作、临床评估以及与其他起搏技术的比较等方面都有新的研究成果出现。其可行性、有效性和安全性已基本得到验证,但其长期预后仍需更大样本量和更长随访时间的研究结果进一步证实。无导线起搏器已开始在更广泛的临床应用中使用,并且已有相关大样本队列研究的报道。此外,在起搏器远程程控、房颤抗凝及射频导管消融(RFCA)治疗、植入式心律转复除颤器预防心源性猝死等领域也有值得关注的新成果。在临床实践方面,由于新冠疫情,中国的RFCA手术及其他器械植入数量出现波动,但自2020年以来已逐渐恢复。